Relevant publications Myeloid cell Imm

Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies.
Keirsse J, Van Damme H, Van Ginderachter JA, Laoui D. J Leukoc Biol. 2017 Aug;102(2):317-324.

 

The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.
Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, Kiss M, Bolli E, Lahmar Q, Sichien D, Serneels J, Scott CL, Boon L, De Baetselier P, Mazzone M, Guilliams M, Van Ginderachter JA. Nat Commun. 2016 Dec 23;7:13720.

 

M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment.
Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA, Laoui D. Cancer Res. 2016 Jan 1;76(1):35-42.

 

Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L, Mazzone M. Cancer Cell. 2013 Dec 9;24(6):695-709.

 

Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim Y, Karroum O, Jordan B, Carmeliet P, Gysemans C, De Baetselier P, Mazzone M, Van Ginderachter JA. Cancer Res. 2014 Jan 1;74(1):24-30.

 

More publications:
https://www.ncbi.nlm.nih.gov/pubmed?term=Van%20Ginderachter%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=24220244